IP Library › Granted Patent US 12,268,822
Granted Patent B2
US 12,268,822 · App. 18/304,228 · Granted Apr 8, 2025

Methods, systems, and apparatus for modulating or reducing photophobic responses

Inventors: Steven M. Blair (Salt Lake City, UT); Bradley Jay Katz (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
A61M21/02A61N5/0618G02B5/22G02B5/285G02C7/104A61M2021/0044A61N2005/0663A61N2005/0667G02B5/289G02B2207/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,822
App. No.
18/304,228
Granted
Apr 8, 2025
Kind
B2
Abstract

An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.

Claims (98)

1. An apparatus for reducing the frequency and/or severity of photophobic responses by controlling light exposure to melanopsin ganglion cells in a retina, the apparatus comprising an optical filter configured to transmit:

a first amount of light determined by a weighted average across a Gaussian function with central wavelength of about 480 nm and full-width at half-maximum of about 52 nm, the first amount of light being a dose of light experienced by the cis isoform of the melanopsin ganglion cells of a subject (D melan );

a second amount of light determined by a weighted average across a Gaussian function with central wavelength of about 590 nm and full-width at half-maximum of about 40 nm, the second amount of light being a dose of light experienced by the trans isoform of the melanopsin ganglion cells of a subject (D rec,590 ); and

a third amount of light determined by a weighted average across a Gaussian function with central wavelength of about 550 nm and full-width at half-maximum of about 134 nm, the third amount of light is a dose of light experienced over the visual response spectrum (D vis ),

wherein a ratio including the third amount of light and the first amount of light is defined as a first figure of merit (FOM 1 ), the first figure of merit being determined by:

FOM

1

=

1

-

D

m

⁢

e

⁢

l

⁢

a

⁢

n

D

m

⁢

e

⁢

l

⁢

a

⁢

n

(

T

=

1

)

1

-

D

v

⁢

i

⁢

s

D

v

⁢

i

⁢

s

(

T

=

1

)

where D melan (T=1) is the first amount of light in the absence of an optical filter, and D vis (T=1) is the third amount of light in the absence of an optical filter, wherein the first figure of merit of the optical filter is between 0.9 and 1.5, and

wherein a ratio including the third amount of light and the second amount of light is defined as a second figure of merit (FOM 2 ), the second figure of merit being determined by:

FOM

2

=

1

-

D

590

·

rec

D

590

,

rec

(

T

=

1

)

1

-

D

v

⁢

i

⁢

s

D

v

⁢

i

⁢

s

(

T

=

1

)

where D 590,rec (T=1) is the second amount of light in the absence of an optical filter,

wherein the second figure of merit of the optical filter is between 1.25 and 2.0.

2. The apparatus of claim 1 , wherein the first figure of merit FOM 1 is 1.3±0.1.

3. The apparatus of claim 1 , wherein the second figure of merit FOM 2 is 1.425±0.05.

4. The apparatus of claim 1 , wherein the optical filter has chromaticity coordinates of x=0.33±0.03 and y=0.33±0.03.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2023
From: BLAIR, STEVEN M.; KATZ, BRADLEY JAY
To: UNIVERSITY OF UTAH
Reel/Frame 063419/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2023
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 063419/0947 →
Continuity (8)
Continuation 16800951 · Feb 25, 2020
Continuation 16445085 · Jun 18, 2019
Continuation 15673264 · Aug 9, 2017
Continuation In Part 14338182 · Jul 22, 2014
Continuation In Part 14160374 · Jan 21, 2014
Continuation In Part 13979876
Provisional Application 61433344 · Jan 17, 2011
Related Publication 20230248937A1 · Aug 10, 2023
References Cited (158)
US 4527183A · Anthony et al. · 1985 [cited by applicant]
US 5218386A · Levien · 1993 [cited by applicant]
US 5402190A · Waldman · 1995 [cited by applicant]
US 5737045A · Abileah · 1998 [cited by applicant]
US 5946114A · Loiseaux et al. · 1999 [cited by applicant]
US 6420032B1 · Iacovangelo · 2002 [cited by applicant]
US 6610081B2 · Saathoff · 2003 [cited by applicant]
US 7380940B2 · Anderson et al. · 2008 [cited by applicant]
US 7438411B2 · Payne et al. · 2008 [cited by applicant]
US 7556376B2 · Ishak et al. · 2009 [cited by applicant]
US 7854505B2 · Cunningham et al. · 2010 [cited by applicant]
US 7988318B1 · Smith et al. · 2011 [cited by applicant]
US 8345364B2 · Liberman et al. · 2013 [cited by applicant]
US 9606277B2 · Blair et al. · 2017 [cited by applicant]
US 9759848B2 · Blair et al. · 2017 [cited by applicant]
US 9764157B2 · Blair et al. · 2017 [cited by applicant]
US 10234608B2 · Blair et al. · 2019 [cited by applicant]
US 10281627B2 · Blair et al. · 2019 [cited by applicant]
US 10605970B2 · Blair et al. · 2020 [cited by applicant]
US 10914877B2 · Blair et al. · 2021 [cited by applicant]
US 20020044254A1 · Saathoff · 2002 [cited by applicant]
US 20020187347A1 · Halas et al. · 2002 [cited by applicant]
US 20030161257A1 · Yusu et al. · 2003 [cited by applicant]
US 20040085660A1 · Hara · 2004 [cited by applicant]
US 20050074611A1 · Kuehnle et al. · 2005 [cited by applicant]
US 20050149993A1 · Panda et al. · 2005 [cited by applicant]
US 20050164169A1 · Malak · 2005 [cited by applicant]
US 20060092374A1 · Ishak · 2006 [cited by applicant]
US 20060158732A1 · Ramadan · 2006 [cited by applicant]
US 20060189113A1 · Vanheusden et al. · 2006 [cited by applicant]
US 20070012189A1 · Kang et al. · 2007 [cited by applicant]
US 20070282437A1 · Hermitte et al. · 2007 [cited by applicant]
US 20070298242A1 · Huo · 2007 [cited by applicant]
US 20080065177A1 · Casper et al. · 2008 [cited by applicant]
US 20080221674A1 · Blum et al. · 2008 [cited by applicant]
US 20090022995A1 · Graham et al. · 2009 [cited by applicant]
US 20100149483A1 · Chiavetta, III · 2010 [cited by applicant]
US 20100246009A1 · Polley et al. · 2010 [cited by applicant]
US 20100328763A1 · Seo et al. · 2010 [cited by applicant]
US 20110009542A1 · Gong et al. · 2011 [cited by applicant]
US 20110060062A1 · Wang et al. · 2011 [cited by applicant]
US 20110075263A1 · Liberman et al. · 2011 [cited by applicant]
US 20110223255A1 · Thiesen et al. · 2011 [cited by applicant]
US 20120043512A1 · Liu et al. · 2012 [cited by applicant]
US 20130062637A1 · Reed et al. · 2013 [cited by applicant]
US 20130100443A1 · Li et al. · 2013 [cited by applicant]
US 20130130018A1 · Poncelet et al. · 2013 [cited by applicant]
US 20130258456A1 · Hashimura et al. · 2013 [cited by applicant]
US 20140135570A1 · Blair et al. · 2014 [cited by applicant]
US 20140160569A1 · Blair et al. · 2014 [cited by applicant]
US 20140303504A1 · Stankovic et al. · 2014 [cited by applicant]
US 20140320806A1 · Cohen-Tannoudji et al. · 2014 [cited by applicant]
US 20140327967A1 · Blair et al. · 2014 [cited by applicant]
US 20140329336A1 · Moriya et al. · 2014 [cited by applicant]
US 20150138661A1 · Blair et al. · 2015 [cited by applicant]
US 20150168616A1 · Blair et al. · 2015 [cited by applicant]
US 20150234207A1 · Koifman · 2015 [cited by applicant]
US 20160282532A1 · Le et al. · 2016 [cited by applicant]
US 20170336545A1 · Blair et al. · 2017 [cited by applicant]
US 20190154894A1 · Blair et al. · 2019 [cited by applicant]
US 20190310405A1 · Blair et al. · 2019 [cited by applicant]
US 20200192011A1 · Blair et al. · 2020 [cited by applicant]
US 20210103080A1 · Blair et al. · 2021 [cited by applicant]
CN 103969725A · 2014 [cited by applicant]
CN 104115054A · 2014 [cited by applicant]
CN 111148482A · 2020 [cited by applicant]
DE 102005044031A1 · 2007 [cited by applicant]
DE 102007007777A1 · 2008 [cited by applicant]
DE 102011050870A1 · 2012 [cited by applicant]
EP 1566833A2 · 2005 [cited by applicant]
EP 1743691A1 · 2007 [cited by applicant]
EP 1991365B1 · 2014 [cited by applicant]
EP 2896423A1 · 2015 [cited by applicant]
JP 2004508106A · 2004 [cited by applicant]
JP 2005254446A · 2005 [cited by applicant]
JP 2006523593A · 2006 [cited by applicant]
JP 2007021473A · 2007 [cited by applicant]
JP 2007199421A · 2007 [cited by applicant]
JP 2008203377A · 2008 [cited by applicant]
JP 2009526132A · 2009 [cited by applicant]
JP 2009536549A · 2009 [cited by applicant]
JP 2010271022A · 2010 [cited by applicant]
JP 2011506747A · 2011 [cited by applicant]
JP 2011511330A · 2011 [cited by applicant]
JP 2012041534A · 2012 [cited by applicant]
JP 2012063715A · 2012 [cited by applicant]
JP 2013127489A · 2013 [cited by applicant]
JP 2014531058A · 2014 [cited by applicant]
JP 2015509742A · 2015 [cited by applicant]
JP 2017533449A · 2017 [cited by applicant]
JP 2018172778A · 2018 [cited by applicant]
JP 2020530587A · 2020 [cited by applicant]
JP 2020190749A · 2020 [cited by applicant]
KR 100611682B1 · 2006 [cited by applicant]
WO 0220079A1 · 2002 [cited by applicant]
WO 2004021071A1 · 2004 [cited by applicant]
WO 2004077453A2 · 2004 [cited by applicant]
WO 2006097794A1 · 2006 [cited by applicant]
WO 2007011331A2 · 2007 [cited by applicant]
WO 2007133197A1 · 2007 [cited by applicant]
WO 2009100195A1 · 2009 [cited by applicant]
WO 2010111499A1 · 2010 [cited by applicant]
WO 2012154535A1 · 2012 [cited by applicant]
WO 2012177296A1 · 2012 [cited by applicant]
WO 2013039117A1 · 2013 [cited by applicant]
WO 2013084176A1 · 2013 [cited by applicant]
WO 2014011581A2 · 2014 [cited by applicant]
WO 2015073933A1 · 2015 [cited by applicant]
WO 2016014713A1 · 2016 [cited by applicant]
WO 2016148984A1 · 2016 [cited by applicant]
WO 2019032348A1 · 2019 [cited by applicant]
Balzers et al., “Design of Optical Minus Filters,” Journal of the Optical Society of America, vol. 61, No. 3, (1971). [cited by applicant]
Berson et al., “Phototransduction by Retinal Ganglion Cells That Set the Circadian Clock,” Science, 295 (2002). [cited by applicant]
Blackburn “FL-41 Tint Improves Blink Frequency, Light Sensitivity, and Functional Limitations in Patients with Benign Essential Blepharospasm,” Ophthalmology 2009 116(5) 997-1001. [cited by applicant]
Czeisler “Sleep and Circadian Rhythms in Humans,” Cold Spring Harbor Symposia on Quantitative Biology, 2007, 72:579-97. [cited by applicant]
Czeisler, “The Effect of Light on the Human Circadian Pacemaker,” CIBA Foundation Symposium, 1995; 183:254-90. [cited by applicant]
Duffe et al. “Entertainment of the Human Circadian System by Light.” Journal of Biological Rhythms, 2005 20(4):326-38. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,478, mailed on Dec. 15, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,478, mailed on Jun. 2, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,564, mailed on Aug. 25, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,564, mailed on Jul. 30, 2018. [cited by applicant]
Final Office Action received for U.S. Appl. No. 15/673,264, mailed on Jan. 10, 2019. [cited by applicant]
Good, P., Taylor, R. and Mortimer, M. (1991), The Use of Tinted Glasses in Childhood Migraine. Headache: The Journal of Head and Face Pain, 31: 533-536. doi:10.1111/j.1526-4610.1991.hed3108533.x. [cited by applicant]
Hannibal J. Roles of PACAP-containing retinal ganglion cells in circadian timing. Int Rev Cytol. 2006;251:1-39. doi:10.1016/S0074-7696(06)51001-0. [cited by applicant]
Hoggan et al., “Thin Film Optical Notch Filter Spectacle Coatings for the Treatment of Migraine and Photophobia,” In Press. Journal of Clinical Neuroscience, 2016. [cited by applicant]
International Search Report and Written Opinion for PCT/US2012/021500 dated May 8, 2012. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/041610 dated Oct. 2, 2015. [cited by applicant]
International Search Report and Written Opinion for PCT/US2016/044835 dated Oct. 12, 2018. [cited by applicant]
International Search Report for PCT/US2014/065848 dated Mar. 5, 2015. [cited by applicant]
Kojima et al., “UV-Sensitive Photoreceptor Protein OPN5 in Humans and Mice,” PLoS One 6(10): e26388. doi: 10.1371/journal.pone.0026388. [cited by applicant]
Larouche et al., “OpenFilters: Open-Source Software for the Design, Optimization, and Synthesis of Optical Filters,” Applied Optics, vol. 47, No. 13, (2008). [cited by applicant]
Mure LS, Cornut PL, Rieux C, et al. Melanopsin bistability: a fly's eye technology in the human retina. PLoS One. 2009;4(6):e5991. Published Jun. 24, 2009. doi:10.1371/journal.pone.0005991. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/251,510, mailed on Jun. 16, 2020, 8 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/800,951, mailed on Mar. 28, 2022, 7 pages. [cited by applicant]
Noseda et al. “A Neural Mechanism for Exacerbation of Headache by Light” Nature Neruosciencs, 2010 13:2 239-45. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,564, mailed on Nov. 2, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 15/673,264, mailed on Sep. 20, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 16/445,085, mailed on Sep. 27, 2019. [cited by applicant]
Office Action received for U.S. Appl. No. 13/979,876, mailed on Feb. 25, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/160,374, mailed on Apr. 7, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/160,374, mailed on Oct. 20, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/338,182, mailed on Nov. 29, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Aug. 25, 2017. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Jun. 22, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Nov. 3, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,564, mailed on Jan. 10, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,564, mailed on Jun. 5, 2017. [cited by applicant]
Satchidananda Panda et al., “Illumination of the Melanopsin Signaling Pathway,” Science, 307 (2005). [cited by applicant]
Wang et al., “Theory and Applications of Guided-Mode Resonance Filters,” Applied Optics, vol. 32, No. 14, (1993). [cited by applicant]
Bogoslovov et al. Effect of Silica Nanoparticles on the Local Segmental Dynamics in Poly(vinyl acetate), Macromolecules, 2008, vol. 41, pp. 1289-1296. [cited by applicant]
Khlebtsov et al. “The Effect of the Size, Shape, and Structure of Metal Nanoparticles on the Dependence of Their Optical Properties on the Refractive Index of a Disperse Medium,” Optics and Spectroscopy, vol. 98, No. 1,… [cited by applicant]
Sahoo et al. “Residual Polyvinyl Alcohol Associated with Poly (D,L-lactide-co-glycolilde) Nanoparticles Affects Their Physical Properties and Cellular Uptake,” Journal of Controlled Release, vol. 82, 2002, pp. 105-114. [cited by applicant]
Willets et al. “Localized Surface Plasmon Resonance Spectroscopy and Sensing,” Annual Review in Physical Chemistry, vol. 58, 2007, pp. 267-297. [cited by applicant]
European Search Report received for EP Patent Application No. 23189866.9, mailed on Nov. 7, 2023, 9 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/021500, mailed on Jul. 25, 2013, 11 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/044835, mailed on Feb. 20, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/044835, mailed on Oct. 12, 2018, 9 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/122,773, mailed on Aug. 30, 2024, 14 pages. [cited by applicant]